JP2023515675A5 - - Google Patents
Info
- Publication number
- JP2023515675A5 JP2023515675A5 JP2022552573A JP2022552573A JP2023515675A5 JP 2023515675 A5 JP2023515675 A5 JP 2023515675A5 JP 2022552573 A JP2022552573 A JP 2022552573A JP 2022552573 A JP2022552573 A JP 2022552573A JP 2023515675 A5 JP2023515675 A5 JP 2023515675A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- kit
- use according
- administered
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026037122A JP2026097988A (ja) | 2020-03-05 | 2026-03-09 | Pd-1アンタゴニスト、ctla4アンタゴニストおよびレンバチニブまたはその薬学的に許容される塩の組合せを用いる癌を治療する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062985500P | 2020-03-05 | 2020-03-05 | |
| US62/985,500 | 2020-03-05 | ||
| PCT/US2021/020858 WO2021178657A1 (en) | 2020-03-05 | 2021-03-04 | Methods for treating cancer using a combination of a pd-1 antagonist, a ctla4 antagonist, and lenvatinib or a pharmaceutically acceptable salt thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026037122A Division JP2026097988A (ja) | 2020-03-05 | 2026-03-09 | Pd-1アンタゴニスト、ctla4アンタゴニストおよびレンバチニブまたはその薬学的に許容される塩の組合せを用いる癌を治療する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023515675A JP2023515675A (ja) | 2023-04-13 |
| JP2023515675A5 true JP2023515675A5 (cg-RX-API-DMAC7.html) | 2024-03-11 |
Family
ID=77614229
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022552573A Pending JP2023515675A (ja) | 2020-03-05 | 2021-03-04 | Pd-1アンタゴニスト、ctla4アンタゴニストおよびレンバチニブまたはその薬学的に許容される塩の組合せを用いる癌を治療する方法 |
| JP2026037122A Pending JP2026097988A (ja) | 2020-03-05 | 2026-03-09 | Pd-1アンタゴニスト、ctla4アンタゴニストおよびレンバチニブまたはその薬学的に許容される塩の組合せを用いる癌を治療する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026037122A Pending JP2026097988A (ja) | 2020-03-05 | 2026-03-09 | Pd-1アンタゴニスト、ctla4アンタゴニストおよびレンバチニブまたはその薬学的に許容される塩の組合せを用いる癌を治療する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230118596A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4114464A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2023515675A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220149740A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115443152A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021178657A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023003032A (es) * | 2020-09-15 | 2023-06-01 | Merck Sharp & Dohme Llc | Terapia de combinacion de un antagonista de pd-1 y un antagonista de lag3 y lenvatinib o una sal farmaceuticamente aceptable del mismo para el tratamiento de pacientes con cancer. |
| WO2023160517A1 (zh) * | 2022-02-22 | 2023-08-31 | 齐鲁制药有限公司 | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 |
| US20250376525A1 (en) * | 2022-06-28 | 2025-12-11 | Qilu Pharmaceutical Co., Ltd. | Pharmaceutical composition comprising mixed antibody of anti-ctla4 and anti-pd1 and therapeutic use thereof |
| EP4722358A1 (en) * | 2023-06-02 | 2026-04-08 | Ajou University Industry-Academic Cooperation Foundation | Glycerol dehydratase variant and use thereof |
| WO2025002264A1 (zh) * | 2023-06-30 | 2025-01-02 | 默沙东有限责任公司 | 包含偶联物的药物组合的治疗方法和用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201690912A1 (ru) * | 2013-11-05 | 2016-10-31 | Когнейт Биосервисис, Инк. | Комбинации ингибиторов контрольных точек и терапевтических средств для лечения рака |
| CN105296433B (zh) * | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | 一种ctla4抗体、其药物组合物及其用途 |
| KR20240064733A (ko) * | 2015-03-04 | 2024-05-13 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| HRP20201334T1 (hr) * | 2015-04-17 | 2020-11-27 | Bristol-Myers Squibb Company | Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba |
| CN110505882A (zh) * | 2017-03-31 | 2019-11-26 | 默沙东公司 | 用pd-1的拮抗剂和抗ctla4抗体的组合治疗癌症的组合物和方法 |
| CA3060695A1 (en) * | 2017-05-02 | 2018-11-08 | Merck Sharp & Dohme Corp. | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
| CN119792515A (zh) * | 2018-02-13 | 2025-04-11 | 默沙东有限责任公司 | 用抗pd-1抗体和抗ctla-4抗体治疗癌症的方法 |
| WO2019222075A1 (en) * | 2018-05-14 | 2019-11-21 | Merck Sharp And Dohme Corp. | Biomarkers for a combination therapy comprising lenvatinib and a pd-1 antagonist |
| EP4008730A4 (en) * | 2019-08-02 | 2023-09-06 | Akeso Pharmaceuticals, Inc. | BISPECIFIC ANTI-CTLA4-ANTI-PD-1 ANTIBODY AND ITS USES |
-
2021
- 2021-03-04 JP JP2022552573A patent/JP2023515675A/ja active Pending
- 2021-03-04 CN CN202180028866.1A patent/CN115443152A/zh active Pending
- 2021-03-04 US US17/801,409 patent/US20230118596A1/en active Pending
- 2021-03-04 WO PCT/US2021/020858 patent/WO2021178657A1/en not_active Ceased
- 2021-03-04 KR KR1020227034434A patent/KR20220149740A/ko active Pending
- 2021-03-04 EP EP21764706.4A patent/EP4114464A4/en active Pending
-
2026
- 2026-03-09 JP JP2026037122A patent/JP2026097988A/ja active Pending